HRP20240102T1 - Monoklonsko protutijelo koje antagonizira i inhibira vezanje između humanog pd-1 antigena i njegovog liganda, postupak njegove priprave i primjena - Google Patents
Monoklonsko protutijelo koje antagonizira i inhibira vezanje između humanog pd-1 antigena i njegovog liganda, postupak njegove priprave i primjena Download PDFInfo
- Publication number
- HRP20240102T1 HRP20240102T1 HRP20240102TT HRP20240102T HRP20240102T1 HR P20240102 T1 HRP20240102 T1 HR P20240102T1 HR P20240102T T HRP20240102T T HR P20240102TT HR P20240102 T HRP20240102 T HR P20240102T HR P20240102 T1 HRP20240102 T1 HR P20240102T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- variable region
- seq
- human
- cdr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (11)
1. Monoklonsko protutijelo koje antagonizira i inhibira vezanje humanog PD-1 antigena na njegov ligand, naznačeno time da sadrži prvu i drugu varijabilnu regiju: prva varijabilna regija je varijabilna regija lakog lanca protutijela, od kojih su aminokiselinske sekvence CDR 1, CDR 2 i CDR 3 prikazane u SEQ ID BR.: 3, SEQ ID BR: 4 i SEQ ID BR: 5, dok je druga varijabilna regija varijabilna regija teškog lanca protutijela, od kojih su aminokiselinske sekvence CDR 1, CDR 2 i CDR 3 prikazane u SEQ ID BR: 8, SEQ ID BR: 9 i SEQ ID BR: 10, respektivno i gdje je prva navedena varijabilna regija varijabilna regija lakog lanca protutijela, sa sekvencom aminokiselina prikazanom u SEQ ID BR: 11, dok je navedena druga varijabilna regija varijabilna regija teškog lanca protutijela, sa sekvencom aminokiselina prikazanom u SEQ ID NO: 12.
2. Protutijelo ili njegov derivat prema zahtjevu 1, naznačeno time da sadrži spomenutu varijabilnu regiju lakog lanca protutijela i konstantnu regiju lakog lanca ljudskog protutijela, kao i zglobnu regiju, CH1, CH2 i CH3 spomenutog varijabilnog teškog lanca protutijela. regija i konstantna regija teškog lanca ljudskog protutijela.
3. Protutijelo ili njegov derivat prema zahtjevu 2, naznačeno time da je navedena konstantna regija lakog lanca ljudskog protutijela iz kapa lanca ljudskog protutijela ili lambda lanca protutijela, a navedena teška konstantna regija ljudskog protutijela je iz humanog podtipa IgG1, IgG2, IgG3 ili IgG4.
4. DNA molekula ili gen koji kodira protutijelo ili njegov derivat prema zahtjevu 1, naznačen time što je nukleotidna sekvenca varijabilne regije lakog lanca protutijela prikazana u SEQ ID BR: 13, a nukleotidna sekvenca varijabilne regije teškog lanca protutijela prikazana je u SEQ ID BR: 14.
5. Ekspresijski vektor, naznačen time što sadrži DNA molekularni slijed prema zahtjevu 4 i slijed regulacije ekspresije operativno povezan s njim.
6. Rekombinantna stanica domaćina, naznačena time da je transformirana iz ekspresijskog vektora navedenog u zahtjevu 5.
7. Rekombinantna stanica domaćina prema zahtjevu 6, naznačena time da navedena rekonstitucijska stanica domaćin eksprimira protutijelo ili njegov derivat prema zahtjevu 1.
8. Farmaceutski pripravak, naznačen time da sadrži farmaceutski učinkovitu količinu protutijela prema zahtjevu 1 i farmaceutski prihvatljiv nosač.
9. Farmaceutski pripravak prema zahtjevu 8, naznačen time da se koristi u liječenju raka.
10. Farmaceutski pripravak za upotrebu prema zahtjevu 9, naznačen time da je to rak debelog crijeva.
11. Metoda za pripremu protutijela ili njegovog derivata prema zahtjevu 1, naznačena time da metoda uključuje sljedeće korake:
a) Osigurati ekspresijski vektor koji sadrži DNA molekularni slijed prema Zahtjevu 4 i slijed regulacije ekspresije operativno povezan s njim;
b) Transformirajte stanice domaćina ekspresijskim vektorom navedenim u koraku a);
c) Kultura stanica domaćina dobivenih iz koraka b) pod uvjetima prikladnim za ekspresiju navedenog protutijela; i
d) Nabavite navedena protutijela odvajanjem i pročišćavanjem tekućine kulture stanica domaćina afinitetnom kromatografijom.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710262053.4A CN106939049B (zh) | 2017-04-20 | 2017-04-20 | 拮抗抑制人pd-1抗原与其配体结合的单克隆抗体及其制备方法与应用 |
| EP17906230.2A EP3613768B1 (en) | 2017-04-20 | 2017-06-21 | Monoclonal antibody antagonizing and inhibiting binding between human pd-1 antigen and ligand thereof, preparation method therefor and application thereof |
| PCT/CN2017/089282 WO2018192089A1 (zh) | 2017-04-20 | 2017-06-21 | 拮抗抑制人pd-1抗原与其配体结合的单克隆抗体及其制备方法与应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240102T1 true HRP20240102T1 (hr) | 2024-03-29 |
Family
ID=59464668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240102TT HRP20240102T1 (hr) | 2017-04-20 | 2017-06-21 | Monoklonsko protutijelo koje antagonizira i inhibira vezanje između humanog pd-1 antigena i njegovog liganda, postupak njegove priprave i primjena |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11345754B2 (hr) |
| EP (1) | EP3613768B1 (hr) |
| JP (1) | JP6928971B2 (hr) |
| CN (1) | CN106939049B (hr) |
| ES (1) | ES2969235T3 (hr) |
| HR (1) | HRP20240102T1 (hr) |
| HU (1) | HUE065954T2 (hr) |
| PL (1) | PL3613768T3 (hr) |
| RS (1) | RS64987B1 (hr) |
| WO (1) | WO2018192089A1 (hr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3510157B1 (en) | 2016-09-08 | 2023-05-31 | 2seventy bio, Inc. | Pd-1 homing endonuclease variants, compositions, and methods of use |
| CN108299561B (zh) * | 2018-01-02 | 2020-11-13 | 暨南大学 | 一种pd-1纳米抗体及其克隆表达方法与应用 |
| CN108997497B (zh) | 2018-03-30 | 2022-02-25 | 华兰基因工程有限公司 | 特异结合人质膜膜泡关联蛋白pv-1的单克隆抗体及其制备方法与应用 |
| CN110878122B (zh) * | 2018-09-06 | 2023-07-28 | 上海张江生物技术有限公司 | 重组抗pd-l1单克隆抗体 |
| CN109053892B (zh) | 2018-09-19 | 2021-03-26 | 苏州思坦维生物技术股份有限公司 | 特异结合人及猴cd38抗原的单克隆抗体及其制备方法与应用 |
| CN113330113A (zh) * | 2018-12-10 | 2021-08-31 | 蓝鸟生物公司 | Pdcd-1归巢核酸内切酶变体 |
| WO2021006199A1 (ja) | 2019-07-05 | 2021-01-14 | 小野薬品工業株式会社 | Ｐｄ－１／ｃｄ３二重特異性タンパク質による血液がん治療 |
| TW202120550A (zh) | 2019-08-08 | 2021-06-01 | 日商小野藥品工業股份有限公司 | 雙特異性蛋白質 |
| WO2021088904A1 (zh) * | 2019-11-08 | 2021-05-14 | 先声生物医药科技有限公司 | 抗人程序性死亡配体-1(pd-l1)的抗体及其用途 |
| CN113563470B (zh) * | 2020-04-29 | 2023-02-10 | 广州昂科免疫生物技术有限公司 | 结合tigit抗原的抗体及其制备方法与应用 |
| WO2024227176A1 (en) | 2023-04-28 | 2024-10-31 | OncoC4, Inc. | Combinations of anti-ctla-4 antibodies and anti-pd-1 antibodies and therapeutic uses thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003288675B2 (en) * | 2002-12-23 | 2010-07-22 | Medimmune Limited | Antibodies against PD-1 and uses therefor |
| AU2006244885B2 (en) | 2005-05-09 | 2011-03-31 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| KR101888321B1 (ko) | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| WO2008156712A1 (en) | 2007-06-18 | 2008-12-24 | N. V. Organon | Antibodies to human programmed death receptor pd-1 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| EP4331604B1 (en) | 2008-12-09 | 2025-03-05 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| EP2545078A1 (en) * | 2010-03-11 | 2013-01-16 | UCB Pharma, S.A. | Pd-1 antibody |
| LT2699264T (lt) * | 2011-04-20 | 2018-07-10 | Medimmune, Llc | Antikūnai ir kitos molekulės, kurios jungiasi prie b7-h1 ir pd-1 |
| PT2992017T (pt) * | 2013-05-02 | 2021-01-29 | Anaptysbio Inc | Anticorpos dirigidos contra a morte programada 1 (pd-1) |
| CN103242448B (zh) | 2013-05-27 | 2015-01-14 | 郑州大学 | 一种全人源化抗pd-1单克隆抗体及其制备方法和应用 |
| CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| AU2013400609B9 (en) * | 2013-09-13 | 2020-03-05 | Beigene Switzerland Gmbh | Anti-PD1 antibodies and their use as therapeutics and diagnostics |
| CN104558177B (zh) * | 2013-10-25 | 2020-02-18 | 苏州思坦维生物技术股份有限公司 | 拮抗抑制程序性死亡受体pd-1与其配体结合的单克隆抗体及其编码序列与用途 |
| CN104560884A (zh) * | 2013-10-25 | 2015-04-29 | 苏州思坦维生物技术有限责任公司 | 拮抗抑制程序性死亡受体pd-1与其配体结合的单克隆抗体及分泌它的杂交瘤细胞系与用途 |
| UA119659C2 (uk) | 2013-12-12 | 2019-07-25 | Шанхай Хенжуй Фармасьютикал Ко., Лтд. | Антитіло до pd-1, його антигензв'язуючий фрагмент та їхнє медичне застосування |
| JOP20200094A1 (ar) * | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| WO2016008067A1 (zh) | 2014-07-14 | 2016-01-21 | 惠州市吉瑞科技有限公司 | 一种吸烟控制方法、吸烟控制电路以及电子烟 |
| PL3177644T3 (pl) * | 2014-08-05 | 2021-06-14 | MabQuest SA | Immunologiczne reagenty wiążące do PD-1 |
| CA3175979A1 (en) * | 2014-12-22 | 2016-06-30 | Pd-1 Acquisition Group, Llc | Anti-pd-1 antibodies |
| CN105061597B (zh) * | 2015-06-09 | 2016-04-27 | 北京东方百泰生物科技有限公司 | 一种抗pd-1的单克隆抗体及其获得方法 |
| SG10201914109VA (en) * | 2015-08-11 | 2020-02-27 | Wuxi Biologics Cayman Inc | Novel anti-pd-1 antibodies |
| LT3368572T (lt) * | 2015-10-02 | 2022-07-25 | Symphogen A/S | Anti-pd-1 antikūnai ir kompozicijos |
-
2017
- 2017-04-20 CN CN201710262053.4A patent/CN106939049B/zh active Active
- 2017-06-21 ES ES17906230T patent/ES2969235T3/es active Active
- 2017-06-21 JP JP2019556961A patent/JP6928971B2/ja active Active
- 2017-06-21 HU HUE17906230A patent/HUE065954T2/hu unknown
- 2017-06-21 WO PCT/CN2017/089282 patent/WO2018192089A1/zh active Application Filing
- 2017-06-21 PL PL17906230.2T patent/PL3613768T3/pl unknown
- 2017-06-21 EP EP17906230.2A patent/EP3613768B1/en active Active
- 2017-06-21 RS RS20231241A patent/RS64987B1/sr unknown
- 2017-06-21 US US16/606,779 patent/US11345754B2/en active Active
- 2017-06-21 HR HRP20240102TT patent/HRP20240102T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3613768C0 (en) | 2023-11-22 |
| CN106939049B (zh) | 2019-10-01 |
| ES2969235T3 (es) | 2024-05-17 |
| US20200277376A1 (en) | 2020-09-03 |
| CN106939049A (zh) | 2017-07-11 |
| JP6928971B2 (ja) | 2021-09-01 |
| JP2020517264A (ja) | 2020-06-18 |
| RS64987B1 (sr) | 2024-01-31 |
| EP3613768B1 (en) | 2023-11-22 |
| HUE065954T2 (hu) | 2024-07-28 |
| WO2018192089A1 (zh) | 2018-10-25 |
| EP3613768A1 (en) | 2020-02-26 |
| US11345754B2 (en) | 2022-05-31 |
| EP3613768A4 (en) | 2020-06-17 |
| PL3613768T3 (pl) | 2024-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20240102T1 (hr) | Monoklonsko protutijelo koje antagonizira i inhibira vezanje između humanog pd-1 antigena i njegovog liganda, postupak njegove priprave i primjena | |
| CN109651507B (zh) | 一种激动型4-1bb单克隆抗体 | |
| HRP20191704T1 (hr) | Multispecifična protutijela | |
| CN110035773B (zh) | 新型抗ctla4抗体 | |
| CN104479020B (zh) | 一种抗pd-1人源抗体 | |
| RU2012131671A (ru) | Способ полипептидной модификации для очистки полипептидных мультимеров | |
| FI3389699T3 (fi) | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja | |
| RU2018113505A (ru) | Il-8-связывающие антитела и их применения | |
| RU2451689C2 (ru) | Новые антипролиферативные антитела | |
| JP7476997B2 (ja) | 二重特異性抗体 | |
| JP2013537416A5 (hr) | ||
| EP3707162A1 (en) | Il2rbeta/common gamma chain antibodies | |
| CN106519025A (zh) | 利用cdr的氨基酸取代来改变抗体等电点的方法 | |
| AU2017255888B2 (en) | Humanized anti-BASIGIN antibodies and the use thereof | |
| HRP20191277T1 (hr) | Anti-cd26 antitijela i njihove primjene | |
| BR112020020637A2 (pt) | anticorpo anti-pd-l1, fragmento de ligação ao antígeno ou variante do mesmo, anticorpo biespecífico, composição farmacêutica e uso dos mesmos para aliviar ou tratar tumores | |
| RU2017145662A (ru) | Моноклональные антитела и способы их применения | |
| JP2014530001A5 (hr) | ||
| CN108276492B (zh) | 抗pd－l1单克隆抗体及其应用 | |
| CN108314734A (zh) | 抗pd－1单克隆抗体及其应用 | |
| FI4200018T3 (fi) | Anti-par-2-vasta-aineet ja niiden käyttömenetelmät | |
| KR20150134319A (ko) | 인간화 항 hmgb1 항체 또는 그의 항원 결합성 단편 | |
| KR101886772B1 (ko) | 완전한 인간 ｈｅｒ２ 항체의 돌연변이화된 항체, 이를 인코딩하는 유전자 및 이의 용도 | |
| JP2020500179A (ja) | 免疫チェックポイント阻害剤と組み合わせた治療的使用のための抗ｂａｇ３抗体 | |
| JP2024028850A (ja) | 抗ｐｄ－ｌ１抗体及びその製薬用途 |